PostScript

MATTERS ARISING

Antiphospholipid antibodies and rheumatoid arthritis

We read with interest the letter entitled “Antiphospholipid antibodies and RA: presence of \( \beta_2 \)-GP1 independent aCL” by Bonnet et al published in the *Annals* in March 2001. We believe that the letter needs additional clarification owing to inconsistencies in the terminology, methodology of antiphospholipid antibody (aPL) detection, and determination of positive values.

The use of the term “anticardiolipin antibodies” was somewhat misleading. The term was introduced and abbreviated as “aCL”, a group of antibodies detected in many conditions, but the \( \beta_2 \)-glycoprotein I (\( \beta_2 \)-GPI) dependence of the aCL was not defined, even though the authors focused on \( \beta_2 \)-GPI independent aCL. It is generally agreed that the term aCL, if not stated otherwise, defines both \( \beta_2 \)-GPI dependent and \( \beta_2 \)-GPI independent antibodies.

There were some potential methodological errors in determining \( \beta_2 \)-GPI independent aCL. It was shown that antibodies against \( \beta_2 \)-GPI (anti-\( \beta_2 \)-GPI) from patients with the antiphospholipid syndrome (APS) have the ability to bind \( \beta_2 \)-GPI in complexes with cardiolipin only if the \( \beta_2 \)-GPI concentration in solution is high enough. The threshold concentration of \( \beta_2 \)-GPI was found to be just about 2 \( \mu \)g/ml, because no binding of anti-\( \beta_2 \)-GPI was seen when serum samples were diluted 1:200 or more. As the physiological concentration of \( \beta_2 \)-GPI in human serum is approximately 200 \( \mu \)g/ml, the threshold binding concentration is reached at a serum dilution of 1:100. In the presence of a relatively high concentration of endogenous \( \beta_2 \)-GPI, the statement that antibodies detected by this method are exclusively \( \beta_2 \)-GPI independent is unjustified, as the sera containing high titres of anti-\( \beta_2 \)-GPI might have yielded positive results by the method described in the letter.

The definition of antibody units in the letter is not clear and using Harris’s standards for \( \beta_2 \)-GPI independent aCL is not appropriate. With the use of Harris’s standards, the units should be abbreviated as GPL (for IgG) and MPL (for IgM) as previously defined. However, Harris’s standards were designed for use in the classical aCL ELISA and were prepared by pooling serum samples from patients with APS. Therefore, they contain mainly, or predominantly, \( \beta_2 \)-GPI dependent aCL. \( \beta_2 \)-GPI independent aCL were not defined in those standards and they were not meant as standards for \( \beta_2 \)-GPI independent assays.

The interpretation of anti-\( \beta_2 \)-GPI ELISA as a method to detect \( \beta_2 \)-GPI dependent aCL may not be valid in all cases. It was shown that not all anti-\( \beta_2 \)-GPI binding \( \beta_2 \)-GPI adsorbed on polystyrene high binding plates also recognised \( \beta_2 \)-GPI associated with cardiolipin. We reported this binding pattern for anti-\( \beta_2 \)-GPI in children with atopic dermatitis, and the same was shown also for some patients with autoimmune diseases, including APS.

The method for purification of \( \beta_2 \)-GPI was not described. Because the authors focused on patients with rheumatoid arthritis (RA), it should be ensured that immunoglobulins were specifically removed from the \( \beta_2 \)-GPI preparation. If this purification step was not carried out, traces of immunoglobulins in the \( \beta_2 \)-GPI preparation might have yielded positive results for sera containing high titres of rheumatoid factor (RF). In fact, all sera containing IgM anti-\( \beta_2 \)-GPI also had RF and the authors already suspected that this might be due to non-specific binding involving RF.

The method for determining cut off values was not explained and the number of normal human sera (NHS) included in the study as negative controls was not given. From the data presented in the letter, one may conclude that the cut off values were arbitrarily set at 20 % for both IgG and IgM isotypes of \( \beta_2 \)-GPI independent aCL and for anti-\( \beta_2 \)-GPI. We recently compared the sensitivity of anti-\( \beta_2 \)-GPI ELISA and classical aCL ELISA. The results showed great differences between their sensitivities and therefore also between the cut off values calibrated by the same standards. In addition, the authors did not report the proportion of NHS positive for each assay and the values of positive samples compared with patients with RA. Instead, they just referred to one study, which is only one of the several published estimations of aPL in healthy subjects.

We would like to support our criticism by adding some data about aPL in our patients with RA. We randomly selected 53 serum samples from patients fulfilling the ARA criteria for RA and 53 NHS as negative controls. The samples were tested for anti-\( \beta_2 \)-GPI, \( \beta_2 \)-GPI dependent aCL, and \( \beta_2 \)-GPI independent aCL. The assays were calibrated with \( \beta_2 \)-GPI dependent monoclonal aCL (IgG and IgM anti-\( \beta_2 \)-GPI ELISA and \( \beta_2 \)-GPI independent aCL ELISA) and positive in-house standards (all IgA assays and \( \beta_2 \)-GPI independent aCL). The cut off values for anti-\( \beta_2 \)-GPI were set as described by calculating the mean + 2 SD of logarithms of absorbance values for NHS and the 95th centile value of 32 NHS for both \( \beta_2 \)-GPI dependent and \( \beta_2 \)-GPI independent aCL. For the anti-\( \beta_2 \)-GPI determination, we used affinity purified \( \beta_2 \)-GPI adsorbed on Costar high binding plates as previously described. The \( \beta_2 \)-GPI preparation did not contain any immunoglobulins. \( \beta_2 \)-GPI independent aCL were tested as described in the letter, but the sera were diluted 1:200. Serum samples were tested simultaneously for both \( \beta_2 \)-GPI dependent aCL on the same plate by adding \( \beta_2 \)-GPI in parallel duplicate wells. The final concentration of \( \beta_2 \)-GPI was 10 \( \mu \)g/ml. This experimental design enabled direct comparison of binding to cardiolipin coated wells in the presence and absence of \( \beta_2 \)-GPI. For the final determination of \( \beta_2 \)-GPI dependent binding, the values obtained in wells without \( \beta_2 \)-GPI were subtracted from the values measured in wells with added \( \beta_2 \)-GPI. The patients’ histories were evaluated for the occurrence of arterial or venous thrombosis and recurrent fetal loss. Statistical analysis was performed with the \( \chi^2 \) test where appropriate.

Table 1 presents the frequency of positive sera in each group (NHS, RA, RA-RF positive, and RA-RF negative). The frequency of increased anti-\( \beta_2 \)-GPI, \( \beta_2 \)-GPI dependent aCL, and \( \beta_2 \)-GPI independent aCL was higher in patients with RA than in controls, but the difference was significant only for anti-\( \beta_2 \)-GPI. There were no differences in the frequency of

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Frequency of anti-( \beta_2 )-GPI, ( \beta_2 )-GPI dependent aCL, and ( \beta_2 )-GPI independent aCL in patients with rheumatoid arthritis (positive or negative for RF) and normal controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>No of positive samples:</td>
<td>Anti-( \beta_2 )-GPI†</td>
</tr>
<tr>
<td></td>
<td>IgG</td>
</tr>
<tr>
<td>NHS (n=53)</td>
<td>1</td>
</tr>
<tr>
<td>RA (n=33)</td>
<td>3</td>
</tr>
<tr>
<td>RA-RF (n=36)</td>
<td>1</td>
</tr>
<tr>
<td>RA-RF (n=17)</td>
<td>1</td>
</tr>
</tbody>
</table>

\( \alpha CL \) Anticardiolipin antibodies; \( \beta_2 \)-GPI, \( \beta_2 \)-glycoprotein I; NHS, normal human sera; RA, rheumatoid arthritis; RF, rheumatoid factor.

If you have a burning desire to respond to a letter published in the *Annals of the Rheumatic Diseases*, why not make use of our “rapid response” option?

Log on to our website (www.annrheumdis.com), find the paper that interests you, and send your response via email by clicking on the “eLetters” option in the box at the top right hand corner.

Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read eLetters” on our homepage.

The editors will decide as before whether also to publish it in a future paper issue.

www.annrheumdis.com

Downloaded from http://ard.bmj.com/ on April 30, 2017 - Published by group.bmj.com
any type of antibodies between the RF positive and negative patients. One patient (male, 66 years old) had a history of deep venous thrombosis and pulmonary embolism together with positive anti-β2GP1 and β2GP1 dependent aCL of IgA isotype. Interestingly, 3/11 RA sera which showed binding to β2GP1 adsorbed on a high binding plate did not recognise β2GP1 associated with cardiolipin, as already reported. In contrast, 3/9 RA sera binding β2GP1 complexed with cardiolipin did not recognise β2GP1 adsorbed on the surface of high binding plates. This phenomenon probably reflects the heterogeneous nature of anti-β2GP1 in RA, which may differ in fine specificity from anti-β2GP1 in APS.

The sera from our patients with RA exhibited an even higher frequency of β2GP1 independent aCL than that reported in the letter. As expected from reported data, the presence of β2GP1 independent aCL was not associated with signs of APS in our patients. We also found that the addition of β2GP1 (10 μg/ml) lowered the binding of β2GP1 independent aCL by about 50%, most probably owing to the competition between β2GP1 independent aCL and β2GP1 for the same binding sites on cardiolipin.

In conclusion, patients with RA may have anti-β2GP1 and β2GP1 dependent aCL, which might be associated with the signs of APS. The importance of distinguishing β2GP1 independent aCL has not been fully clarified. It seems likely that β2GP1 independent aCL do not confer an increased risk for APS in RA.

A Ambrozic, B Bozic, M Hojnik, T Kveder, B Rozman
Department of Rheumatology, University Medical Centre Ljubljana, Slovenia

Correspondence to: Dr A Ambrozic, Department of Rheumatology, University Medical Centre, Vodnikova 62, 1000 Ljubljana, Slovenia (Slovenia); ales.ambrozic@ml.uni.si

References


Authors’ reply
In response to the comments of Ambrozic et al. we would like to supply some information to the data published earlier in the Annals.2,3

The term “anticardiolipin antibodies” (aCL) is classically used to designate antibodies directed against the cardiolipin antigen and detected in sera, or to the dependence of aCL on β2-glycoprotein 1 (β2GP1). It is assessed by an enzyme linked immunosorbent assay (ELISA) test using exogenous β2GP1 in blocking buffer (containing fetal calf sera or bovine sera). In our unfractionated serum solution did not contain bovine or calf sera but only purified bovine serum albumin. So, this method was adapted to detect antibodies directed against cardiolipin antigen alone and not against the complexes of cardiolipin bound to exogenous β2GP1. This method justified the terminology of β2GP1 independent aCL for sera containing aCL without anti-β2GP1 antibodies. Absence of anti-β2GP1 antibodies was shown by another ELISA test specific for the detection of these antibodies. Both ELISAs were used to screen all sera.

The concentration of β2GP1 contained in human serum is not significant at a 1/100 dilution (the dilution employed to screen our sera), in comparison with the 10% of calf sera added to the test as source of exogenous β2GP1 (β2GP1) in the assays used for the detection of β2GP1 dependent aCL. In addition, the sera containing aCL (detected by an ELISA without addition of exogenous β2GP1) did not react with β2GP1 in the other ELISA test specifically designed to detect anti-β2GP1 autoantibodies, and therefore which could detect hypothetically high titres of anti-β2GP1 antibodies contained in these sera.

Harris’s standards were used after calibration of our positive control sera from patients with proven antiphospholipid syndrome (APS), which were used for the positive controls in every microtitration plate. We used these for the detection of aCL in our previous studies employing ELISA test without bovine or calf sera.7 The antiphospholipid antibodies, including aCL, are directed against several anti-genetic targets. Among them, some epitopes are located on the cardiolipin alone. These data were described by Harris when aCL were first characterised in systemic lupus erythematosus serum reacting in a VDRL test. By radioimmunoassay, he showed that antibodies contained in these sera were directed against cardiolipin contained in liposomes used as a reagent of the VDRL test.8 These reagents were constituted by lipids alone without any other cofactor such as β2GP1. So, Harris’s standard can also be used to detect aCL directed only against phospholipid and not against the complex β2GP1-cardiolipin. In addition, the use of Harris’s standards seems to be better adapted to the detection of polyclonal anti-phospholipid antibodies, than monoclonal human aCL used as internal controls.

The β2GP1 used in our assay was provided to Stag laboratories (Asnière, France) and was purified from human sera. We used sodium dodecyl sulphate-polyacrylamide gel electrophoresis and Western blotting to ensure that this purified protein was not contaminated.

For every antibody determination, aCL and anti-β2GP1 autoantibodies, normal levels were established from soddis of a large number of normal subjects (blood donors) as previously described.9 In this study, 50 serum samples, provided by consenting healthy donors, were tested as controls. Cut-off values were determined as the mean and two standard deviations of the arbitrary units obtained by reference to positive and negative internal standards. For every serum, we defined the corrected optical density (OD) (that is, the mean OD obtained in three coated wells minus the OD corresponding to non-specific binding of each serum, obtained in three uncoated wells). The cut off values defined for anti-β2GP1 and anti-cardiolipin ELISA were 20 units in both tests. The standards for the anti-β2GP1 test were prepared to positive controls from patients with APS and were used according to previous studies.10

In contrast with the report of Ambrozic et al., we did not find raised levels of aCL or anti-β2GP1 antibodies in normal sera. The percentage of positive normal serum samples was <3%. These differences between our results and those of Ambrozic et al. are probably associated with a differing sensitivity and specificity of the methods between the two laboratories.

M O Jauberteaue
Department of Immunology, University of Limoges, France

C Bonnet
Department of Rheumatology, University of Limoges, France

Correspondence to: Dr C Bonnet, Department of Rheumatology, Centre Hospitalier de Limoges, 2 Avenue Martin-Luther King, 87042 Limoges cedex, France

References


Methotrexate and postoperative complications
Grennan et al report the safety of continued methotrexate in the perioperative period. Previous investigators have despaired of answering this question definitively owing to the difficulty in recruiting subjects. It is reassuring to see that methotrexate use throughout the postoperative period does not interfere with wound healing or increase the incidence of complications.

Despite this important finding, we believe that the results of this study should be regarded with some reservation: continuation of methotrexate throughout the perioperative period should be accompanied by significant caution. The elderly and those with renal impairment are at increased risk of methotrexate-related pancytopenia.11,12 Indeed, in a community based, observational study of methotrexate use in 460 patients we found the
perioperative period to be especially hazardous for patients with renal impairment and sepsis. Two subjects developed pancytopenia under these conditions, one of whom died.

Although all consecutive patients were included in the study by Grennan et al, it is unclear whether Wrightington Hospital is a tertiary referral centre. Renal impairment is an important comorbidity, although no comment is made about the prevalence of this in the study group. It is important to note that this is a study of methotrexate use in elective surgery. We suggest caution should be taken in patients with renal impairment (best assessed by creatinine clearance) and in the elderly with comorbid cardiovascular disease when approaching surgery. Sudden volume loss, bleeding, or dehydration will impair methotrexate excretion and increase the risk of bone marrow toxicity in this group. It may be prudent in those assessed as at high risk of this complication to stop methotrexate one week before the operation and restart treatment one or two weeks after the operation, depending on postoperative progress. This time period without methotrexate treatment will not result in control in the vast majority of patients, although after four weeks without treatment, most will have a flare of the disease.

A Wluka
Department of Epidemiology and Preventive Medicine, Monash University, Australia
R Buchbinder
Department of Epidemiology, Cabrini Hospital, Malvern, Australia and Monash University, Australia
S Hall
Cabrini Medical Centre, Malvern, Australia
G Littlejohn
Monash Medical Centre, Clayton, Australia
Correspondence to: Dr A Wluka, Department of Epidemiology and Preventive Medicine, Monash University, Central and Eastern Clinical School, Alfred Hospital, Prahran, Victoria 3181, Australia

References


Letters

Proximal myopathy and bone pain as the presenting features of coeliac disease

It is rare for coeliac disease to present only with symptoms of osteomalacia, without the classic symptoms of diarrhoea, steatorrhea, and abdominal discomfort.1 A 22 year old woman presented with 18 months of a waddling gait disturbance. Hip and back x rays were normal. She experienced bone pain when being hugged, when laughing, or coughing, and had difficulty standing up from a low chair and holding her arms up to blow-dry her hair. She had extreme tiredness and thought she might have lost some weight, but there were no gastrointestinal symptoms. On examination, she was pale and had difficulty squatting and holding her arms above her head.

Investigations showed a mild anaemia secondary to B thalassaemia minor and iron deficiency. Other investigations disclosed a raised alkaline phosphate of 1375 U/l (normal 30–120 U/l), reduced red blood cell folate level of 290 nmol/l (>300 nmol/l), corrected calcium of 1.75 mmol/l (2.15–2.65 mmol/l), phosphatase 1.0 mmol/l (0.8–1.4 mmol/l), 25-hydroxy vitamin D <5 nmol/l (15–110 nmol/l), and raised parathormone 53.1 pmol/l (1.0–6.5 pmol/l).

Investigations were carried out for a malabsorption syndrome. Antigliadin, antidentomyosial, and antiglutaminase antibodies were strongly positive, and a small bowel biopsy showed almost total villous atrophy, confirming the diagnosis of coeliac disease.

A bone scan demonstrated increased activity throughout the skeleton, consistent with secondary hyperparathyroidism. Osteoporosis was demonstrated by dual emission x ray absorptiometry estimation of bone mineral density, with the lumbar spine measuring 0.882 g/cm² (2.65 SD below the young adult female mean) and the neck of the femur 0.633 g/cm² (2.9 SD below the mean).

Treatment involved a gluten free diet, ergocalciferol 3000 IU daily, calcium carbonate 600 mg twice a day, slow release ferrous sulphate 350 mg daily, and folic acid 5 mg daily.

Within two months her bone pain and tiredness resolved and her strength had returned to normal. Calcium was within the normal range, and alkaline phosphate reduced to 374 U/l. Bone mineral density had increased markedly after 12 months of treatment, with the lumbar spine increasing by 37% to 1.204 g/cm² (mean level for young adult women), and the neck of the femur by 39% to 0.878 g/cm² (0.8 SD below the mean). She had also gained more than 7 kg in weight, and repeat gastroscopy and duodenal biopsy were normal.

Osteomalacia is now an uncommon disease, and even more uncommon is the presenting symptom of coeliac disease. Since its first description in 1965, there have been several case reports of coeliac disease presenting with bone pain, proximal myopathy, radiographic findings of pseudo fractures and Looser’s zones, or secondary hyperparathyroidism evident on bone scan.1,2 Most patients were middle aged women, responded within six months to treatment with a gluten-free diet, supplemental calcium, and vitamin D, and in some cases with the addition of bisphosphonates.3 A recent case finding study of coeliac disease showed that many patients in fact present with non-gastrointestinal symptoms, of which anaemia is the most common.4

Hypocalcaemia in coeliac disease is caused by reduced gut absorption of calcium as a consequence of reduced levels of the fat soluble vitamin D. It is also due to reduced absorptive surface area, secondary hyperparathyroidism, and calcium lost in the stools by binding to unabsorbed dietary fatty acids to form insoluble calcium soaps.5

Secondary hyperparathyroidism can develop even if in this case of increased bone turnover. Low bone mineral density is probably due to a combination of hypocalcaemia, impaired bone mineralisation, and reduced exercise because of skeletal pain and proximal weakness.1,4

Early diagnosis of coeliac disease is important because untreated patients have an increased risk of gastrointestinal lymphomas. Usefulness of screening blood tests include determination of antigliadin and antidentomyosial antibodies. They have a high sensitivity and specificity, with a negative predictive value of around 95% .6 There is a genetic influence on the susceptibility to coeliac disease, with a 10% prevalence rate among first degree relatives. On screening our patient’s relatives, one of two siblings was also found to have coeliac disease. A strong association has been found with HLA-DR3 and DR5/DR7.7

Treatment with a gluten-free diet with subsequent villous restitution on repeat biopsy has been associated with rapid gains and even normalisation of bone mineral density; the greater the degree of osteopenia, the more rapid the gain.8 The change is due to improvement of calcium and vitamin D status, leading to remineralisation of the large volume of unmineralised osteoid matrix.4 Introduction of hormone replacement therapy in women approaching the menopause, and bisphosphonates in patients with osteoporotic fractures, should also be considered.4

Osteomalacia presenting with muscle weakness and aches may be the only presenting features of coeliac disease. Prompt treatment and diagnosis is important because treatment with a gluten-free diet and medical treatment including vitamin D may lead to rapid and effective recovery.9

M Wong, J Scally, K Watson, J Best
University of Melbourne Department of Medicine, St Vincent’s Hospital, Melbourne, Victoria, Australia; wongbeil@bigpond.com

References

more than 45 minutes, five swollen joints, five tender joints, and erythrocyte sedimentation rate (Westergren) more than 45 mm/1st h. Both plasma and lysed PBMC samples were read on atomic absorption spectrophotometer (Perkin Elmer, Norwalk, CT) at a wavelength of 213.8 nm for Zn and 324.7 nm for Cu. The atomic absorption spectrophotometer was calibrated with reference standards obtained from Sigma Chemicals Company (St Louis, MA).

Thirty nine patients (31 women) with a mean (SD) age of 36.2 (8.3) years (range 18–52) and mean disease duration of 55.8 (36.6) months (range 6–168). Twenty patients had inactive and 19 patients active disease, respectively. Twenty two healthy controls (14 women), well matched for age (mean age 34.2 (6.2) years, range 20–56) with the two patient groups, were studied at the same time. Both patients and controls were of middle socioeconomic status. Table 1 shows the plasma and PBMC levels of Zn and Cu.

Our results are in agreement with earlier studies which showed that plasma Zn levels are significantly lower and plasma Cu levels significantly higher in patients with active RA.1,2 Additional evidence is shown here that PBMC levels of these elements have an inverse relation with plasma levels.

With acute inflammation, the acute phase response may move Zn into the liver and the reduced plasma concentration may not be indicative of overall deficiency.3 Possibly also, PBMCs may be an additional site to which Zn and Cu may be transported during active disease. PBMCs may be an additional site to which Zn and Cu may be transported during active disease. In the liver where it is absorbed and attached to ceruloplasmin. Thus the findings of plasma and PBMC Cu levels may merely be a reflection of an acute phase response, and the alterations may be due to increased hepatic synthesis of ceruloplasmin. The effect of concomitant drugs must be considered. The number of patients receiving non-steroidal anti-inflammatory drugs and second line drugs was similar. None of the patients received corticosteroids in the preceding eight weeks.

It would be premature to speculate about a possible role for supplementation with Zn and Cu for patients with RA. From the results shown in this study, patients with inactive RA had similar levels of Zn and Cu as controls. If the diet of patients with active RA were deficient in Zn (as shown by plasma levels) it would be unlikely to contain an excess of Zn and vice versa for PBMC levels. The more plausible explanation would be that this represents a redistribution of trace elements between plasma and PBMCs, and a control of inflammation would lead to levels close to those seen in controls. Hence, further studies need to be carried out on paired samples in a cohort of patients, once the disease is active and again when it becomes inactive. If plasma Zn levels decrease with the control of inflammation and attain the levels of controls then there would be no indication for dietary supplementation with these metals.

A Wanchu, A Sud, P Bambery
Department of Internal Medicine, Post-Graduate Institute of Medical Education and Research, Chandigarh, 160012 India
R Prasad, V Kumar
Department of Biochemistry, Post-Graduate Institute of Medical Education and Research, Chandigarh

Correspondence to: Dr Wanchu; awanchu@glide.net.in

References

Essential cryoglobulinaemia (type 1) in three patients characterised by Raynaud’s phenomenon, arthralgia-arthritis, and skin lesions

The relevance of monoclonal gammapathy in relation to rheumatic disorders has recently been reviewed. Monoclonal gammapathy or
paraproteins can be detected in healthy adults and in different disease entities like amyloidosis, malignant proliferative disorders,1 associated with hepatitis C infections,2 and rheumatic diseases.3 The overall incidence of paraproteins in adults is about 1%. This incidence rises in patients over 70 and increases with age. When a paraprotein is detected and no underlying disease is present, the condition is referred to as a monoclonal gammopathy of undetermined significance.

Owing to their immunochromical properties, paraproteins can be precipitated by lowering the temperature below 37°C. In this way they form an essential part of the so-called cryoglobulins. When cryoglobulins are detected in the serum of a patient, this finding is usually associated with the coexistence of paraproteins. Recently, three patients with a clinical picture of a necrotising vasculitis associated with an essential cryoglobulinemia (type 1) were admitted to our department. The causative relationship between the cryoglobulinemia and the clinical symptoms were studied by the reduced severity of the clinical signs when paraprotein levels were decreased.

Case reports

Patient A was a 69 year old man who, in May 1999, developed extremely painful purpura of the upper part of the third finger of his left hand. In the following days the upper part of his left hand became necrotic. Angiography of his arteries showed normal vessels. Immune electrophoresis showed the presence of 8 g/l of an M component (IgGκ). An assay for the detection of cryoglobulinemia was positive.

Laboratory examination showed a paraprotein (8 g/l) combined with a cryoglobulinaemia (type 1) and necrosis of the skin has been described as the upper part of her foot. While waiting for the complete demarcation so that an amputation could be planned, she developed a sepsis and died.

Few patients with essential cryoglobulinemia type 1 have been reported. Until now a defined clinical syndrome could never be associated with cryoglobulins. Overall Raynaud's phenomenon and necrosis of the skin has been described as in our three patients. None of our three patients showed abnormalities on angiographic examination, which may indicate that only the small vessels are affected in the disease process.

In our patients we were able to show that the cryoglobulins were formed by the monoclonal immunoglobulin. When the serum concentration of the cryoglobulin was reduced, the disease symptoms in our patients improved. These cases suggest that a paraprotein found in patients with a rheumatic syndrome is not only indicative of a developing malignancy or other disease but may also be interpreted as a causative agent. We conclude that paraproteins seen in rheumatic syndromes have a role in the pathogenesis and should be treated when serious sympoms are present.

J G den Hollander
Department of Internal Medicine, Zuiderziedeziehuis, Rotterdam, Amsterdam
A J G Swaak
Department of Rheumatology, Zuiderziedeziehuis, Groene Hilleduik 315, 3075 EA Rotterdam, The Netherlands

Correspondence to: Dr Swaak

References


Cryoglobulinemia as presenting manifestation of infective endocarditis

Seromunnomological alterations, including antibodies and/or cryoglobulins, are common in infective endocarditis (IE); however, specific autoimmune disorders, such as cryoglobulinemia vasculitis (CV) associated with IE have seldom been described.6 CV is related to the vascular deposition of circulating immune complexes, mainly cryoglobulins, and comple-ment 7 in 70–90% of patients with CV a triggering role of hepatitis C virus (HCV) has been suggested.2 We report the case of two patients who showed a typical CV with severe neurological involvement as the presenting manifestation of underlying IE.

Case 1

In November 1994 a 63 year old woman presented with fever, purpura, paraesthesia, and pseudoatopic gait. Her past clinical history was unremarkable except for a prostatic implant of the left hip four years previously. Table 1 shows the main cliniceroserological features. Repeated blood cultures were negative. Neurological examination showed abnormal tactile sensation of the arms and legs; mild idiomotor slowing down; shaky movements; and unsteady gait. An electro-physiological study recorded a moderate seniormotodal neurophysiological examination, abdominal echography, and echocardiography were normal. Cutaneous purpura biopsy disclosed a leucocytoclastic vasculitis. Truncocuneaphic magnetic resonance imaging showed a slightly weighted high signal intensity, punctiform lesions at the white matter consistent with brain vasculitis. Thus a central and peripheral neurophysiological examination of the CV was established, and prednisone (50 mg) combined with cyclophosphamide (100 mg) was given daily. However, the patient's clinical status progressively worsened and, finally, she died owing to cardiorespiratory failure (table 1) following month of treatment. Necropsy disclosed chronic endocardial vegetations on the left sided valves infected by Kanguella.

Case 2

In January 1999 a 75 year old woman with no risk factors for infections presented with fever, purpura, and arthreaplasias. Table 1 shows the main clinical and laboratory features suggestive of CV. Prednisone (25 mg/day) was started, with a rapid clinical improvement. One month later, she had an exacerbation of purpura, acroparaesthesias, and impairment of distal muscle strength. An electrophysiological study confirmed a sensoriomotor peripheral neuropathy. Thus a higher steroid dose (50 mg/day) was given. A week later fever persisted and the patient complained of precordial pain and cardiac murmurs were found. A chest x ray examination and transoesophageal echocardiography detected cardiomegaly and endocardial vegetations on the treated valve; in addition, Staphylococcus aureus infection was shown by repeated blood cultures. Despite appropriate antibiotic treatment, the patient died one month later because of severe, refractory heart failure.

Discussion

Our two patients show some interesting peculiarities: the unusual presentation of IE

www.annrheumdis.com
as CV with severe neurological involvement; and the difficulty of making a timely diagnosis of IE by routine investigations. In both cases, the clinically prevalent CV symptoms with systemic features and seroimmunological features in two female patients with infective (bacterial) endocarditis, at the first visit

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Epidemiological, clinical, and seroimmunological features in two female patients with infective (bacterial) endocarditis, at the first visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td>Patient 2</td>
</tr>
<tr>
<td>Age (years)</td>
<td>63</td>
</tr>
<tr>
<td>Disease duration (weeks)</td>
<td>7</td>
</tr>
<tr>
<td>Streptococcus</td>
<td></td>
</tr>
<tr>
<td>Weakness</td>
<td>Severe</td>
</tr>
<tr>
<td>Arthritis</td>
<td>Recurrent</td>
</tr>
<tr>
<td>Hepatopathy</td>
<td>Absent</td>
</tr>
<tr>
<td>Nephropathy</td>
<td>Absent</td>
</tr>
<tr>
<td>Neurological involvement</td>
<td>Peripheral + central</td>
</tr>
<tr>
<td>Cardiac symptoms</td>
<td>Absent</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>83</td>
</tr>
<tr>
<td>CRP (normal &lt;5 mg/l)</td>
<td>53</td>
</tr>
<tr>
<td>WBC (normal 5–10×10^9/l)</td>
<td>89 000</td>
</tr>
<tr>
<td>Neutrophils (%)</td>
<td>87</td>
</tr>
<tr>
<td>Lymphocytes (%)</td>
<td>10</td>
</tr>
<tr>
<td>γ Globulinaemia (g/l)</td>
<td>19.5</td>
</tr>
<tr>
<td>RF (normal &lt;20 IU/ml)</td>
<td>575</td>
</tr>
<tr>
<td>C3 (normal 500–1200 mg/l)</td>
<td>930</td>
</tr>
<tr>
<td>C4 (normal 200–550 mg/l)</td>
<td>&lt;60</td>
</tr>
<tr>
<td>Cryocrit, % [cryotyp]</td>
<td>0.5 [g/g-l]</td>
</tr>
<tr>
<td>Hepatitis virus markers</td>
<td>Negative</td>
</tr>
</tbody>
</table>

*HbsAg, anti-HBs, anti-HbcIgM, anti-Hbc; anti-HCV by ELISA and RIBA; anti-EBV IgM, anti-HIV.

References


ANCA antibodies in Graves’ disease

Several drugs have been associated with antineutrophil cytoplasmatic antibodies (ANCA) positivity—namely, hydralazine, penicillamine, allopurinol, and propylthiouracil.3

Although propylthiouracil is often implicated in the induction of ANCA positive vasculitis,4 other antithyroid drugs, such as carbimazole and thiamazole, have been linked.5 Furthermore, ANCA positivity has been described in the course of Graves’ disease without vasculitis.6

This study aimed at determining the frequency and specificity of ANCA in a series of patients with Graves’ disease. Diagnosis of the disease was based on typical signs and symptoms of hyperthyroidism, raised serum triiodothyronine and thyroxine, very low or undetectable thyroid stimulating hormone, and increased thyroid radioactive iodine uptake. All patients had been receiving treatment with carbimazole (30–45 mg) for at least two months. None of the patients were treated with propylthiouracil or any drug affecting the immune function. ANCA antibodies were determined by indirect immunofluorescence (IF) on ethanol fixed granulocytes, as described elsewhere.7 Staining patterns were described as cANCA, when a diffuse granular cytoplasmatic staining with central accentuation was seen, as pANCA, when a perinuclear pattern was observed, and as ANCA when a distinct, homogeneous, non-granular cytoplasmatic staining pattern was seen. Antiantibodies against proteinase 3 and myeloperoxidase (MPO) were detected by enzyme linked immunosorbent assay (ELISA; Orgentec) as described elsewhere.8 Hospital University Germans Trias i Pujol is a 533 bed hospital situated on the outskirts of Barcelo-

Correspondence to: Dr Luca La Civita, Rhenumatology Department of Lucania, Azienda Ospedaliera S Carlo, Contrada Macchia Romana, 85100 Potenza, Italy

C Ferri
Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy

ANCA (IIF) were detected in 21 (60%) of the serum samples. The titre ranged from 1/40 to 1/2560. The immunofluorescence staining pattern was as follows: nine (26%) pANCA, seven (20%) cANCA, and five (14%) ANCA. ELISA was positive in just one case (for MPO)—in the patient with an IIF titre of 1/2560.

Our results are very similar to those of Afla-

Created on April 30, 2017 - Published by group.bmj.com

PostScript

www.annrheumdis.com
Human MPO and human thyroid peroxidase (TPO) share global similarities which indicate that MPO and TPO are members of the same gene family. Therefore, it seems conceivable that MPO autoantibodies may cross react with TPO. Findings suggesting such a relationship were reported by Haapala et al. who found antibodies against both TPO and MPO in 19 patients, three with vasculitis and 16 with thyroid disorders. 

There is a need to determine the autoimmune role of ANCA antibodies in Graves’ disease, the precise relation between ANCA and antithyroid drugs and, lastly, the antigens which are responsible for the ANCA positivity.

ANCA positivity in Graves’ disease may be attributable to either antithyroid drugs (thiamazole or propylthiouracil) or to the disease itself.

Lupus relapse after prostaglandin E, administration: activation of a cytokine cascade?

A variety of abnormalities in cytokine production occur in human and murine lupus, but their specific role in lupus pathogenesis is unknown. Recent in vitro studies emphasise the role of prostanoids in the cytokine induction and modulation of the humoral immune response. 9 We present a patient with systemic lupus erythematosus (SLE) who had a relapse after prostaglandin E, (PGE,) administration, which to our knowledge has not been previously reported.

A 25 year old woman was admitted to hospital to receive treatment with IV PGE, owing to severe Raynaud’s phenomenon. Fifteen years previously SLE had been diagnosed according to American Rheumatism Association (ARA) criteria, with renal biopsy proven dense proliferative lupus glomerulonephritis (WHO class IV). A physical examination showed only painful, violaceous, and atrophic finger pads with no signs of systemic inflammatory disease. The chest x ray films were normal and laboratory investigations showed antinuclear antibodies (ANA; titre 1:160) and hypocomplementaemia (C3 0.6 g/l, C4 0.1 g/l), with normal liver, renal, and haematological parameters. Treatment with 40 mg/12 h IV PGE, was started. On the sixth day of treatment the patient began to have chest pain, fever, dyspnoea, and pericardial friction rub. The laboratory showed anaemia, modest thrombocytopenia, and ANA 1:320, with no changes in the rest of the biochemical serum parameters. Echocardiography and chest x ray examination showed moderate pericardial and bilateral pleural effusions. PGE, was withdrawn and oral prednisone, 60 mg/day, was started with prompt improvement in the symptoms.

We investigated the possibility that PGE, mediated cytokine production might be the cause of the relapse of SLE in this patient. Intracellular expression of cytokines in the patient’s T lymphocytes after specific PGE, stimuli (10 ng/ml) was determined by flow cytometry using anticytokine conjugates in combination with surface anti-CD3 (Pharmacgen, San Diego, CA), as previously described. 1 The test performed eight months after the PGE, treatment showed a dramatic rise in interleukin 4 (IL4) production (table 1). It has been suggested that cytokines have an important role in the immune dysregulation seen in lupus prone mice and in patients with SLE. Increasing evidence supports a role for T helper cell type 2 (Th2) cytokines, such as IL4, in promoting and perpetuating B cell hyperactivity and autoantibody formation. 2–4 A change in the proportion of Th2 cytokines might be associated with the polyclonal B cell activation seen in SLE. 5 Restoration of Th1 and Th2 cytokines to levels similar to those seen in healthy mice results in amelioration of the clinical manifestations of an already established experimental SLE. 6 On the other hand, in some studies it has been suggested that PGE, alters the Th1/Th2 balance of T cells to a dominant Th2 response. 7 We suggest that the rise in IL4 production induced by the PGE, as shown in vitro in this patient, may be a marker of dysregulation of the Th1/Th2 profile and might have been the cause of her lupus relapse.

M de la Torre, R Alcázar, D Sánchez de la Nieta, J Nieto, I Ferreras
Nephrology and Services, Complejo Hospitalario Ciudad Real, Spain

J M Urra
Immunology Service, Complejo Hospitalario Ciudad Real, Spain

Correspondence to: Dr M de la Torre, Servicio de Nefrología, Complejo Hospitalario de Ciudad Real, 13002 Ciudad Real, Spain; mtorref@nexo.es

References


Table 1 Intracellular cytokine production after PGE, stimulation in the patient and in an asymptomatic lupus patient who served as a control. Results are shown as the percentage of T lymphocytes with cytokine synthesis

<table>
<thead>
<tr>
<th>IL2</th>
<th>INFγ</th>
<th>IL4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td>PGE,</td>
<td>Basal</td>
</tr>
<tr>
<td>Patient</td>
<td>CC</td>
<td>Control</td>
</tr>
<tr>
<td>Control</td>
<td>Patient</td>
<td>1.6</td>
</tr>
</tbody>
</table>

IL, interleukin; INFγ, interferon γ.

Table 1 Intranuclear cytokine production after PGE, stimulation in the patient and in an asymptomatic lupus patient who served as a control. Results are shown as the percentage of T lymphocytes with cytokine synthesis.

<table>
<thead>
<tr>
<th>IL2</th>
<th>INFγ</th>
<th>IL4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal</td>
<td>PGE,</td>
<td>Basal</td>
</tr>
<tr>
<td>Patient</td>
<td>CC</td>
<td>Control</td>
</tr>
<tr>
<td>Control</td>
<td>Patient</td>
<td>1.6</td>
</tr>
</tbody>
</table>

IL, interleukin; INFγ, interferon γ.

Whole blood was incubated with or without PGE, 10 ng/ml, for six hours in the presence of Brefeldin-A. Cells were stained with FITC-antibodies, and after erythrocyte lysis and permeabilisation, with the phycoerythrin conjugated anticytokines. Samples were analysed by flow cytometry.
Osteocalcin: a marker of disease activity in ankylosing spondylitis?

In rheumatic diseases the synovial concentration of osteocalcin, which represents osteoblast activity, is inversely correlated with the extent of joint inflammation. 1 Synovial and serum osteocalcin correlate positively. 2 In ankylosing spondylitis (AS) the serum concentration of osteocalcin has been reported to be low 3 or normal. 4 Cross sectional studies have shown no significant correlation between osteocalcin serum concentration and erythrocyte sedimentation rate (ESR) or C reactive protein. 5

To answer the question whether serum osteocalcin is a useful marker of disease activity in AS, longitudinal studies may be more sensitive and specific. For this reason changes in serum osteocalcin were correlated with changes in ESR, which is probably still the best marker of inflammation in AS. 6

In 89 patients with ankylosing spondylitis (modified New York criteria; 75 male, 14 female; age 43 (11) years; disease duration 14 (6) years) venous blood was taken at the start of treatment. The ESR was determined according to Westergren, the result at one hour being used for comparison. Serum was frozen at −18°C until further analysis. Osteocalcin was measured in one batch with a commercially available kit (IRMA, Bioct, Vienna; normal range according to the manufacturer 7.5–31.5 ng/ml in men, 3.7–31.7 ng/ml in women). The Mann-Whitney rank sum test was used to test significance.

Results

Of the 89 patients 75 were men and 14 were women with a mean age of 43 (11) years. The mean duration of disease was 14 (6) years. The mean ESR was 38 (15) mm/1st h.

The mean serum osteocalcin concentration was 16.2 (8.0) ng/ml. The osteocalcin serum concentration was within the normal range in 66 of the 89 patients, and 23 patients had increased serum concentrations. Values at the end of treatment were ESR 16 (8, 26.5) mm/1st h, serum osteocalcin 26.1 (18.9, 32.7) ng/ml (no significant changes). The ESR and osteocalcin at the first examination did not correlate significantly (r = 0.07; p = 0.5). The changes in ESR (1 (4, 6) mm/1st h) and changes in osteocalcin (−0.5 (−2.6, 5.7) ng/ml) showed a significant correlation (r = −0.28; p < 0.01).

The results confirm previous findings showing no significant correlation between serum osteocalcin and ESR in cross sectional studies. Changes in osteocalcin after three weeks, however, correlated significantly with changes in ESR, but in view of the weak correlation (r = 0.28) the clinical relevance of serum osteocalcin determination for assessing disease activity seems limited.

References


Takayasu arteritis

Takayasu arteritis is a chronic inflammatory vasculitis that occurs primarily in young women. It occurs worldwide, with greatest prevalence in Asian people. It mainly affects the aorta and its major branches. The Centres for Disease Control and Prevention have broadly defined idiopathic CD4+ T lymphocytopenia as a reproducible depletion of CD4 lymphocytes below 0.3×10^9/l in the absence of HIV infection or other known causes of immunodeficiency. 7 We report a case of Takayasu arteritis with low CD4+ T lymphopenia without evidence of HIV infection in a boy from Turkey.

A 9 year old boy was admitted with a history of dyspnoea, malaise, and cough for four months. Before admission the patient had been prescribed treatment for pneumonia. He had no history of recurrent infection until four months before his admission. There was no parental consanguinity or any immunocompromised person in his family. Physical examination showed a temperature of 36°C, pulse rate of 140 beats/min, respiratory rate of 50/min, and a blood pressure of 110/70 mm Hg. His weight and height were below the fifth centile. He had a gallop rhythm, grade 3/6 pansystolic murmur at the 4th–5th left intercostal space and hepatomegaly. A chest x ray examination showed cardiomegaly and pulmonary oedema. The following laboratory values were obtained: haemoglobin 113 g/l, packed cell volume 0.35, leucocyte count 8.3×10^9/l, platelet count 371×10^9/l, erythrocyte sedimentation rate 71 mm/1st h. Other test findings, including serum electrolytes, blood urea nitrogen, and creatinine, were all normal. Echocardiography showed a dilated cardiomyopathy associated with severe mitral and aortic insufficiency. The patient was treated for heart failure with inotropic agents and furosemide (frusemide) and improved greatly.

At the fourth month of follow up a physical examination showed hypertension and decreased left radial and brachial pulses. A systolic blood pressure difference greater than 10 mm Hg between both arms appeared (right arm, 140/100 mm Hg; left arm, 110/70 mm Hg). Laboratory findings showed increased blood urea nitrogen and creatinine levels. Urine analyses disclosed microalbuminuria and mild proteinuria. Antinuclear antibodies were positive (1:20). Protein electrophoresis showed a decreased serum albumin level, hypergammaglobulinaemia, and increased Ig, globulin. Serum C3 and C4 levels were normal. HLA-B52 was negative. Table 1 shows the immunological findings of this patient. A lymphocyte proliferation test was not carried out on the patient. Enzyme linked immunosorbent assay (ELISA) and polymerase chain reaction tests for HIV-1 and HIV-2 were repeatedly negative, but we did not look for HTLV-1 and HTLV-2. Echocardiography disclosed dilatation of the thoracic aorta and stenosis of the left subclavian artery. Magnetic resonance imaging showed dilatation and irregular contour of the left innominate and descending aorta, and narrowing of the abdominal aorta (fig 1). The patient underwent cardiac catheterisation and aortography. Angiographic examination showed narrowing of the left subclavian artery, dilatation of the thoracic aorta, and occlusion of the superior mesenteric and renal arteries. Moreover, the patient’s left kidney could not be visualised. Takayasu arteritis was diagnosed and the patient received prednisone treatment (2 mg/ kg/day), but he died in the initial steroid treatment period owing to severe cardiac failure. Takayasu arteritis may be the third most common form of childhood vasculitis after...
CD4+ lymphopenia may cause dysgamma-globulinaemia and autoimmune syndromes such as Takayasu arteritis.

S Sebnem Kilic, Ö Bostan, E Çil
Uludag University Medical Faculty, Department of Paediatrics, Gürükle, Bursa 16059, Turkey

Correspondence to: Dr Sebnem Kilic; sebnemk@uludag.edu.tr

References

Recurrent orbital pain and diplopia in a 12 year old boy

A previously healthy 12 year old boy was referred to our unit in May 2000, with a history of persistent ocular pain and recurrent diplopia. The first episode of diplopia had started three years before, when the patient suddenly presented with diplopia and painful periorbital and eyelid oedema. Limited abduction of the right eye was the present. The treating ophthalmologist, after a thorough investigation that excluded brain tumours, orbital masses, and myasthenia gravis, prescribed naproxen (20 mg/kg/day) and systemic corticosteroid treatment (prednisone 1 mg/kg/day, tapered and withdrawn after 15 days); symptoms recovered completely in two weeks. A first magnetic resonance imaging (MRI) scan of the orbit had shown first degree exophthalmus of the right eye and oedema and thickening of the right rectus lateralis muscle (fig 1). Since then the boy had many episodes of ocular pain and diplopia, lasting from two to four weeks, affecting both eyes or alternatively the right and the left, at intervals of one to three months. No sequelae were detected after each relapse.

During the last relapse in October 1999, naproxen and high dose oral corticosteroid treatment (prednisone 2 mg/kg/day) were required to control the disease activity, which subsided over a period of two months. After a short period of wellbeing, the disease flared up again, and recurrence of orbital pain and diplopia was observed when steroids were reduced to 0.5 mg/kg/day. The boy was then admitted to our unit. He appeared well, with no constitutional symptoms. Ocular examination showed mild right exophthalmus and limited motion of both eyes.

Laboratory tests including muscle enzymes (alanine aminotransferase, aspartate aminotransferase, creatine kinase, lactate dehydrogenase, aldolase) values, complement levels, and thyroid function were all within the normal range. Serological tests were negative for viral and bacterial infections, and antibodies against Borrelia burgdorferi were absent. Autoantibodies (antinuclear antibodies, anti-dsDNA, ant cardiolipin, antinuclear antiphospholipid antibodies) were undetectable. Other markers that are considered measures of disease activity in juvenile inflammatory myopathies were evaluated: factor VIII related antigen levels were raised, while neopterin levels and the number of circulating B lymphocytes (CD19 positive cells) were normal. Electrokymography and two dimensional echocardiography excluded a concurrent myocarditis. On the basis of clinical manifestations and immunological parameters systemic lupus erythematosus (SLE), scleroderma (Scl), Crohn’s disease, and thyroiditis were excluded. Orbital MRI showed significant oedema and thickening of the left extrinsic and of the right medial rectus muscles. Electromyography showed increased insertional activity, fibrillations, and positive sharp waves. Ocular myositis was diagnosed. The oral prednisone dose was raised to 30 mg/day, and rapidly tapered after improvement of signs and symptoms. In November 2000, cyclosporin (3 mg/kg/day) was introduced; no relapse of the ocular findings has been seen so far, and prednisone has been progressively reduced to the current dose of 5 mg/day.

The group of idiopathic inflammatory myopathies encompasses a variety of common and uncommon syndromes. The uncommon variants of myositis include orbital myositis, a condition that is rare in adults and even rarer in children.1, 2 Orbital muscle inflammation may be seen in association with other autoimmune diseases, such as SLE, Scl, giant cell myocarditis, and Crohn’s disease. Primary conditions that it is important to distinguish from orbital myositis include thyroid eye disease, ocular myopathies, such as mitochondrial disorders and ocular dystrophies; and orbital pseudotumours. Cellulitis, neoplasms, arteriovenous malformations, and cavernous sinus thrombosis are also included in the differential diagnosis.

Orbital myositis implies orbital inflammation confined to one or more of the extracarotid arteries, including the ophthalmic or the external carotid, or of the anterior communicating or posterior communicating arteries.

Figure 1 Orbital MRI (1, weighted image with contrast) that shows increased signal and size of the right rectus lateralis muscle.
muscles. MRI shows muscle oedema of the affected muscle(s), and is useful for monitoring disease activity. Non-steroidal anti-inflammatory drugs are recommended as first line treatment, but systemic steroids are required in most cases. When steroids fail to control muscle inflammation, methotrexate and cyclosporin have been used with success.1

In our patient, cyclosporin was successful as a steroid sparing agent, because a rapid recurrence of symptoms had always occurred in the past when the corticosteroid dose was reduced, and at present, after six months of cyclosporin treatment, the boy is still asymptomatic and receiving a low dose of steroids.

Despite the rarity of this disorder, our case suggests that diplopia in a child requires rapid and extensive investigation that must include isolated oculo myositis in the differential diagnosis.

F Falcini, G Simonini, M Resti
Department of Paediatrics, University of Florence, Italy

R Cimaz
Paediatric Department, Via Commanda 9, 20122 Milan, Italy, Rolando.Cimaz@unimi.it

References

Sciatica or spinal lymphoma

The involvement of the central nervous system and vertebrae by low grade non-Hodgkin’s lymphoma is rare.1 In this previous “lesson of the month” in this journal, it was implied that there is always a bad prognosis for patients with spinal lymphoma; however, milder cases may also occur.

A 71 year old man presented to us in January 2000 with a three month history of severe low back pain affecting mainly the left lumbar area and buttock, radiating to the outer aspect of the left thigh and calf. He did not have bladder symptoms or history of recent falls. On examination, he looked well; there was no lymphadenopathy. He had restricted back movement with tenderness of lower lumbar spinal processes. Straight leg raising test was restricted to 45° bilaterally, and produced lumbar pain. Neurological examination of the legs showed normal tone, power, and coordination. Knee jerks were reduced, ankle jerks were absent, both plantars were down going, and there was no sensory deficit. He had a past history of epilepsy, which was controlled by phenytoin and phenobarbitone. In 1993 he was admitted with abdominal pain, splenomegaly, and pancytopenia; this was diagnosed as low grade B cell lymphoma and hypereosplenia. Spleenectomy was performed in 1994, his blood count returned to normal, and repeated full blood counts were stable. In 1995 the patient had a fall and severe back pain. A magnetic resonance imaging (MRI) scan showed collapse of T7 and wedging of T4, with evidence of osteoporosis and degenerative changes.

Investigations showed normal serum biochemistry apart from a mild increase of alkaline phosphatase, which was 242 IU/l (normal 60–220). The total white cell count was 24.7×10⁹/l, and differential count showed neutrophils 3.5×10⁹/l (14%), lymphocytes 17×10⁹/l (69%), monocytes 4.0×10⁹/l (16.0%), eosinophils 0.2×10⁹/l (1.0%), basophils 0.0×10⁹/l (0.0%), and occasional atypical lymphocytes were seen in blood film. The erythrocyte sedimentation rate was 4 mm/1st h, a myeloma screen was negative, and prostate specific antigen was normal.

A lumbarosacral spine x ray examination showed biconcave L5 with diffuse osteopenia. Abdominal ultrasound confirmed splenectomy, but no enlarged lymph nodes were detected. A bone isotopic scan showed increased focal activity in the upper lumbar spine and lumbosacral junction, which was compatible with osteoporosis and degenerative changes.

An MRI scan showed extensive infiltration involving vertebral bodies and appendages throughout the lumbosacral spine, being most intense at the biconcave L5; the appearance was consistent with lymphoma or myeloma (fig 1).

During his stay in hospital, the patient’s pain resolved completely after treatment with non-steroidal anti-inflammatory drugs, analgesics, and physiotherapy. His haematologist started treatment of the patient with chlorambucil 10 mg/day for 10 days to be repeated every three weeks, these cycles to be continued for 12 months.

Eight months after the diagnosis of spinal lymphoma, the patient has remained well and active; his back pain is minimal.

In rheumatology, it is essential to differentiate between malignant disease and the more common causes of back pain. Our patient was in a good physical condition, which is unusual for someone with malignancy, his presentation with low back pain appeared to be a typical case of sciatica, and the pain settled down with conventional treatment. Clinically there was no evidence of recurrence of lymphoma—for example, enlarged lymph nodes, weight loss, or fever. However, because of his age at presentation and significant past history thorough investigations were mandatory.

Francesco Morcos
Hope Hospital, Salford M6 8HD, UK

E Smith
Birch Hill Hospital, Rochdale, UK

Correspondence to: Dr F Morcos, Ward C2, Hope Hospital, Salford M6 8HD, UK

References

Unusual complications in the Churg-Strauss syndrome

Although abdominal complications are occasionally reported in the Churg-Strauss syndrome (CSS), bowel perforations, cholecystitis, eosinophilic peritonitis, and oophoritis are very unusual3 and normally resolve after immunosuppressive treatment. We report the case of a patient with CSS with these complications, which was fatal despite proper treatment.

A 64 year old woman with a 13 year history of urticaria, recurrent rhinitis, and asthma was admitted for abdominal pain. An increasing peripheral eosinophilia rising from 1% to 22% in the past five years was detected. Two years before hospital admission an extensive urticarial erythema developed. An abdominal ultrasonography performed during an asthmatic exacerbation when she had no abdominal pain disclosed a thick-walled gall bladder with no echogenic contents. An excised nasal polyp showed polyoid hyperplasia with many eosinophils.
cytes were 18.1×10^9/l with 34% eosinophils. Abdominal ultrasonography and computed tomography (CT) scan showed acalculous cholecystitis. A laparotomy disclosed a purulent peritoneal collection and enlarged inflamed gall bladder and right ovary. A cholecystectomy and right anexectomy were performed. One month after surgery she was readmitted with severe abdominal pain, diarrhoea, and fever. The leucocyte count was 4.89×10^9/l with 22% eosinophils, erythrocyte sedimentation rate (ESR, Westergren) 39 mm/1st h, rheumatoid factor (RF) 765 IU/ml (normal <80), and total IgE 769 IU/ml (normal <100), and serum urea and creatinine, complement C3 and C4, antinuclear antibody and antineutrophil cytoplasmic antibody values were normal or negative. The urine contained 300 mg/l proteins and the sediment 6–8 red cells/low power field, 3–5 leucocytes, and hyaline and hyaline granular casts. An abdomen CT scan showed moderate ascites. The ascitic fluid was serofibrinous with a protein concentration of 55 g/l, a leucocyte count of 1.05×10^9/l with 44% eosinophils, and negative standard and Lowenstein cultures. A diagnosis of CSS was made after reviewing the previous gallbladder and ovariun histopathological specimens (fig 1) and considering the history of asthma, eosinophilia, and nasal polyposis.

Oral methylprednisolone 60 mg/day and cyclophosphamide 100 mg/day were started, with initial clinical improvement. However, the abdominal pain recurred and the patient underwent a second laparotomy after three weeks of treatment. Peripheral blood leucocytes were 18.1×10^9/l with 1% eosinophils. Blood urea, creatinine, and urinary sediment were normal, the ESR fell to 15 mm/1st h and the RF to 435 IU/ml. Purulent fluid in the peritoneal cavity and two perforations in the ileal wall were found. Bowel histology showed wall ulcerations, vascular thrombosis with fibrinoid necrosis, and eosinophil infiltrates. Granulomas were not found. E coli grew from the peritoneal fluid. Intrahepatic metronidazole and gentamicin were started. Four days later a new perforation was suspected and a third laparotomy was done, showing a perforated necrotic small bowel plaque. A broad bowel resection was performed but the patient’s evolution was complicated with high fever, ileus, and vomiting, and she died 48 hours later. A necropsy was not allowed.

Abdominal pain is reported in up to 29–59% of cases of CSS, although many times the cause is unknown. Gastric and colonic ulcers, intestinal fistulas, and small bowel perforations have been described, the last of these being responsible for up to 10% of the CSS deaths. Acalculous cholecystitis, although very rare, may be the first and sometimes the unique manifestation of the CSS. Its evolution is usually torpid, and sometimes only diagnosed at necropsy. Abdominal ultrasonography should be included in the routine screening of patients with CSS.

The right oophoritis was due to vasculitis, with an eosinophilic infiltrate suggestive of CSS (fig 1). As far as we know, this is the first reported case of CSS with confirmed ovariun involvement.

The ascitic fluid, rich in eosinophils, the eosinophil infiltration of major omentum samples and the clinical evolution suggest that the peritoneal involvement was due to the CSS, an extremely rare complication of this disease. Eosinophilic peritonitis was suggested by Lanham owing to serosal involvement in the CSS, but has only been confirmed in one case so far.

The poor response to steroids and cyclophosphamide is striking. Despite the reduction of the peripheral eosinophilia and ESR there was widespread eosinophilic bowel infiltration and vascular fibrinoid necrosis in the laparotomy samples. The evolution of the disease in our patient was catastrophic, especially as she had only one of the five Guillemin CSS mortality associated factors—namely, gastrointestinal involvement.

In summary, CSS abdominal complications should be promptly suspected and treated. In addition, CSS ovariun involvement, although rare, should be included in the differential diagnosis of ovary vasculitis.

**Figure 1** Ovarian eosinophilic infiltration is located in the hilum area, where eosinophilic arthritis is found (haematoxylin and eosin x25, and left lower quadrant x200).
22nd European Workshop for Rheumatology Research
28 Feb–3 Mar 2002; Leiden, The Netherlands
Contact: Professor F C Breedveld, Leiden University Medical Centre, Department of Rheumatology, PO Box 9600, 2300 RC Leiden, The Netherlands
Tel: +31 (0)71 526 3598
Fax: +31 (0)71 526 6672
Email: F.C.Breedveld@lumc.nl
Website: www.ewr.org

Tenth Intensive Applied Epidemiology Course for Rheumatologists
11–15 Mar 2002; Manchester, UK
No previous experience in epidemiology is needed. The course is residential and limited to 25 places.
Contact: Ms Lisa McClair, ARC Epidemiology Unit, University of Manchester, Oxford Road, Manchester M13 9PT, UK
Tel: +44 (0)161 275 5993
Fax: +44 (0)161 275 5043
Email: Lisa@fs1.ser.man.ac.uk

OMERACT VI
11–14 Apr 2002; Bali
Includes two modules: MRI and economics; and four workshops: patients’ perceptions, imaging (healing), progressive systemic scleroderma, minimally important clinical difference and osteoarthritis
Contact: Conference Organisers Q2O, 7 Swann Street, Old Iseworth, Middxex SW7 6RJ, UK; or Peter Brooks, Faculty of Health Sciences, Level 1, Edith Cavell Building, Royal Brisbane Hospital, Herston 4029, Australia
Fax: +44 208569 9553
Email: toni@q2o.co.uk or p.brooks@mailbox.uq.edu.au

British Society for Rheumatology XIXth AGM
23–26 Apr 2002; Brighton, UK
Contact: BSR, 41 Eagle Street, London WC1R 4TL, UK
Website: www.rheumatology.org.uk

4th EULAR Sonography Course
25–28 April 2002; Madrid, Spain
The course is entitled “Practical use of musculoskeletal ultrasonography”
Contact: Esperanzo Naredo
Email: enaredo@cremas.com
Website: www.eular.org/courses and www.sameint.it/eular

10th International Vasculitis and ANCA Workshop
25–28 Apr 2002; Cleveland, Ohio, USA
Contact: Deborah J Bork, The Cleveland Clinic Foundation, Desk A50; Center for Vasculitis Care and Research, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Tel: 216 445 8533
Fax: 216 445 7569
Email: borkd@ccf.org
Website for registration and abstract submission: www.clevelandclinicmeded.com/courses/Vasculitis2002.asp

International Congress: New Trends in Osteoarthritis
9–11 May 2002; Milan, Italy
Contact: Organising Secretariat, O.I.C. S.R.L., Via Fatebenefratelli 19, 20121 Milan, Italy
Tel: +39 02 65 72 700
Fax: +39 02 65 71 270
Email: osteoarthritis@oic.it

10F World Congress on Osteoporosis
10–14 May 2002; Lisbon, Portugal
Contact: IOF Secretariat, 71 cours Albert Thomas, F-69003 Lyon, France
Tel: +33 472 91 41 77
Fax: +33 472 36 90 52
Email: info@iof lyon.org
Website: www.osteofound.org

5th European Conference on Systemic Lupus Erythematosus
26–30 May 2002; Athens, Greece
Chairman Professor HM Moutsopoulos
Secretariat: Amphithirion Congress Organising Bureau
Email: hmoutso@med.uoa.gr
Website: congress@amphitrion.gr

Annual European Congress of Rheumatology
12–15 June 2002; Stockholm, Sweden
Contact: Fred Wys, Executive Secretary
EULAR, Witkonstrasse 15, CH-8032, Zurich, Switzerland
Tel: +41 1 383 9690
Fax: +41 1 383 9810
Email: eular@bluewin.ch
Website: www.eular.org

10th International Congress on Behçet’s Disease
27–29 June 2002; Berlin, Germany
Under the auspices of the International Society for Behçet’s Disease.
Up to eight young investigator awards, each of $500, will be awarded on the basis of abstracts submitted
Contact: Professor Ch C Zouboulis, Department of Dermatology, University Medical Centre Benjamin Franklin, The Free University of Berlin, Fabekstrasse 60–62, 14195 Berlin, Germany
Fax: 49 30 84456908
Email: zoubbere@zedat.fu-berlin.de
Website: www.userpages.fu-berlin.de/~zoubbere
ISBD website: www.behcet.ws

29th Scandinavian Congress of Rheumatology
15–18 Aug 2002; Tromso, Norway
Contact: Hans Nosent, Department of Rheumatology, University Hospital Tromso, Norway
Tel: 47 776 27294
Fax: 47 776 27285
Email: 29scr2002@rito.no or revhan@rito.no

Translational Research in Autoimmunity
21–22 Sep 2002; Pavia, Italy
Contact: Organising secretariat: eventi S.R.L., Corso Cavour, 18/20 - 27100 Pavia, Italy
Email: tra@e20pr.com
Website: www.e20pr.com
Congress website: www.medicine.ucsd.edu/albani/2001meeting

OsteoArthritis Research Society International (OARSI) World Congress
22–25 Sep 2002; Sydney, Australia
Contact: OsteoArthritis Research Society International (OARSI), 2025 M Street, NW, Suite 800, Washington DC 20036, USA
Tel: +1 202 367 1177
Fax: +1 202 367 2177
Email: oarisi@oar.org
Website: www.oar.org

10th International Congress on Antiphospholipid Antibodies
29 Sep–3 Oct 2002; Sicily, Italy
Deadline for abstracts 1 April 2002
Contact: Secretariat, 10th International Congress on Antiphospholipid Antibodies, c/o Kenes International, PO Box 50006, Tel Aviv 61500, Israel
Tel: 972 3 5140018/9
Fax: 972 3 5140077 or 972 3 5172484
Email: aps@kenes.com
Website: www.kenes.com/aps

7th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases
14–17 Oct 2002; Nashville, Tennessee, USA
Contact: Lawrence J Marnett, Biochemistry Department, Vanderbilt University School of Medicine, Nashville TN 37232-0146, USA
Tel: (615) 343 7329
Fax: (615) 343 7534
Website: www.eicosanoids.science.eayne.edu

66th American College of Rheumatology AGM
25–29 Oct 2002; New Orleans, USA
Contact: ACR, Ronald F Olejko, Director of Conferences and Meetings, 1800 Century Place, Suite 250, Atlanta, Georgia 30045–4300, USA
Tel: +1 404 633 3777
Fax: +1 404 633 1870
Email: acr@rheumatology.org
Website: www.rheumatology.org

Third International Meeting on Social and Economic Aspects of Osteoporosis and Osteoarthritis
7–9 November 2002; Barcelona, Spain
Contact: Yolande Pieter Communication, Boulevard Kleayer 108, 4000 Liége, Belgium
Tel: 32 4 254 12 25
Fax: 32 4 254 12 90
Email: ypc@compuserve.com

Certifying Examination in Pediatric Rheumatology
18 Nov 2002
Contact: American Board of Pediatrics, 111 Silver Cedar Court, Chapel Hill, NC 27514-1513, USA
Tel: 919 929 0461
Fax: 919 814 7114 or 919 929 9255
Website: www.abp.org

Future EULAR congresses
18–21 June 2003; EULAR 2003 Lisbon, Portugal
9–12 June 2004; EULAR 2004 Berlin, Germany
8–11 June 2005; EULAR 2005 Vienna, Austria
21–24 June 2006; EULAR 2006 Amsterdam, The Netherlands

www.anrhemundis.com
ANCA antibodies in Graves' disease

M Gumà, A Olivé, M Juan and I Salinas

Ann Rheum Dis 2002 61: 90-91
doi: 10.1136/ard.61.1.90

Updated information and services can be found at:
http://ard.bmj.com/content/61/1/90

References

This article cites 8 articles, 2 of which you can access for free at:
http://ard.bmj.com/content/61/1/90#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/